A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
Phase of Trial: Phase III
Latest Information Update: 25 Sep 2017
At a glance
- Drugs Cannabidiol (Primary)
- Indications Dravet syndrome
- Focus Registrational; Therapeutic Use
- Sponsors GW Pharmaceuticals
- 21 Sep 2017 Planned number of patients changed from 150 to 186.
- 26 Sep 2016 According to a GW Pharmaceuticals media release, the company plans to submit a NDA for cannabidiol (Epidiolex) to the US FDA in the first half of 2017.
- 11 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Jun 2017.